文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

降钙素原指导管理对脓毒症危重癌症患者抗生素疗程的影响(Pro-Can研究):一项随机对照试验

Procalcitonin-Guided Management and Duration of Antibiotic Therapy in Critically Ill Cancer Patients With Sepsis (Pro-Can Study): A Randomized Controlled Trial.
PubMed 文献 · Crit Care Explor · 2024-10-21
一句话结论在脓毒症危重癌症患者中,降钙素原指导管理未缩短抗生素治疗时间(中位停药时间8天 vs 8天,p=0.463)。

该单盲随机对照试验在约旦一家综合多学科癌症医院ICU开展,纳入因疑似感染启动抗生素、符合SEPSIS-3标准且预期ICU停留≥48小时的成人癌症患者,随机分为降钙素原指导组(77例)和标准治疗组(76例),所有患者每日测降钙素原至5天或ICU出院或死亡,降钙素原组按算法指导抗生素管理但临床需要时可推翻算法,标准治疗组对降钙素原水平设盲。主要终点为抗生素停药时间,降钙素原组与标准治疗组中位停药时间均为8天(p=0.463),28天内无抗生素天数中位均为20天(p=0.484),总限定日剂量分别为1541.4和2050.4。结论认为在此类患者中降钙素原指导管理未减少抗生素治疗时间。

要点

  • 降钙素原指导组与标准治疗组中位抗生素停药时间均为8天(IQR 4-11 vs 5-13),p=0.463,无差异。
  • 28天内无抗生素天数中位均为20天(IQR 17-24 vs 16-23),p=0.484,无差异。
  • 降钙素原组总限定日剂量为1541.4,标准治疗组为2050.4,原文未报告该差异的统计学检验。
  • 降钙素原组临床医生可在有临床指征时推翻算法,标准治疗组对降钙素原水平设盲。
  • 纳入患者74%为实体瘤、13%中性粒细胞减少,中位SOFA评分7分,基线降钙素原中位3.4 ng/mL。

适用人群与场景

  • 在ICU接受治疗的成人癌症患者,因疑似感染启动抗生素、符合SEPSIS-3标准、预期ICU停留≥48小时。
  • 研究在约旦一家综合多学科癌症医院开展,为ICU场景。

诊断标准与关键阈值

  • 符合SEPSIS-3标准。
  • 因疑似感染已启动抗生素。
  • 预期ICU停留≥48小时。

处置流程与药物剂量

  • 所有患者每日测量降钙素原,最多5天或至ICU出院或死亡。
  • 降钙素原指导组:提供降钙素原指导算法用于指导抗生素管理,但临床医生如有临床指征可推翻算法。
  • 标准治疗组:ICU临床医生对降钙素原水平设盲。

研究设计与关键结果

  • 研究设计:随机、对照、单盲试验,在约旦一家综合多学科癌症医院开展。
  • 样本量:降钙素原组77例,标准治疗组76例;平均年龄58±14岁,67%为男性,74%为实体瘤,13%为中性粒细胞减少。
  • 基线中位SOFA评分:降钙素原组7(6-10),标准治疗组7(5-9);基线降钙素原中位浓度(ng/mL):降钙素原组3.4(0.8-16),标准治疗组3.4(0.5-26)。
  • 主要终点:降钙素原组与标准治疗组中位抗生素停药时间分别为8(4-11)天和8(5-13)天,p=0.463,无差异。
  • 次要终点:28天内无抗生素天数中位分别为20(17-24)天和20(16-23)天,p=0.484;总限定日剂量分别为1541.4和2050.4。

证据类型、等级与局限

  • 证据类型:随机对照试验(单盲)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在脓毒症危重癌症患者中,降钙素原指导管理未减少抗生素治疗时间,提示该策略在此人群中可能不改变抗生素疗程(原文结论)。
  • 降钙素原指导组允许临床医生推翻算法,标准治疗组对降钙素原设盲。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the effect of procalcitonin-guided management on the duration of antibiotic therapy in critically ill cancer patients with sepsis.

DESIGN: Randomized, controlled, single-blinded trial.

SETTING: A comprehensive multidisciplinary cancer hospital in Jordan.

PATIENTS: Adults with cancer treated in the ICU who were started on antibiotics for suspected infection, met the SEPSIS-3 criteria, and were expected to stay in the ICU greater than or equal to 48 hours.

INTERVENTIONS: Patients were randomized to the procalcitonin-guided or standard care (SC) arms. All patients had procalcitonin measured daily, up to 5 days or until ICU discharge or death. For the procalcitonin arm, a procalcitonin-guided algorithm was provided to guide antibiotic management, but clinicians were allowed to override the algorithm, if clinically indicated. In the SC arm, ICU clinicians were blinded to the procalcitonin levels.

MEASUREMENTS AND MAIN RESULTS: Primary outcome was time to antibiotic cessation. We also evaluated the number of antibiotic-free days at 28 days, hospital discharge, or death, whichever came first, and antibiotic defined daily doses (DDDs). We enrolled 77 patients in the procalcitonin arm and 76 in the SC arm. Mean age was 58 ± 14 (sd) years, 67% were males, 74% had solid tumors, and 13% were neutropenic. Median (interquartile range [IQR]) Sequential Organ Failure Assessment scores were 7 (6-10) and 7 (5-9) and procalcitonin concentrations (ng/mL) at baseline were 3.4 (0.8-16) and 3.4 (0.5-26), in the procalcitonin and SC arms, respectively. There was no difference in the median (IQR) time to antibiotic cessation in the procalcitonin and SC arms, 8 (4-11) and 8 (5-13), respectively (p = 0.463). Median (IQR) number of antibiotic-free days were 20 (17-24) and 20 (16-23), (p = 0.484) and total DDDs were 1541.4 and 2050.4 in the procalcitonin and SC arms, respectively.

CONCLUSIONS: In critically ill cancer patients with sepsis, procalcitonin-guided management did not reduce the duration of antibiotic treatment.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Nazer LH, Awad W, Thawabieh H, et al. Procalcitonin-Guided Management and Duration of Antibiotic Therapy in Critically Ill Cancer Patients With Sepsis (Pro-Can Study): A Randomized Controlled Trial. Crit Care Explor. 2024. PMID: 39431961. doi:10.1097/CCE.0000000000001173

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。